Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.
Front Immunol
; 14: 1152695, 2023.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2286253
ABSTRACT
Introduction:
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is an effective way of protecting individuals from severe coronavirus disease 2019 (COVID-19). However, immune responses to vaccination vary considerably. This study dynamically assessed the neutralizing antibody (NAb) responses to the third dose of the inactivated COVID-19 vaccine administered to people living with human immunodeficiency virus (HIV; PLWH) with different inoculation intervals.Methods:
A total of 171 participants were recruited 63 PLWH were placed in cohort 1 (with 3-month interval between the second and third doses), while 95 PLWH were placed in cohort 2 (with 5-month interval between the second and third doses); 13 individuals were enrolled as healthy controls (HCs). And risk factors associated with seroconversion failure after vaccination were identified via Cox regression analysis.Results:
At 6 months after the third vaccination, PLWH in cohort 2 had higher NAb levels (GMC 64.59 vs 21.99, P < 0.0001) and seroconversion rate (68.42% vs 19.05%, P < 0.0001). A weaker neutralizing activity against the SARSCoV-2 Delta variant was observed (GMT 3.38 and 3.63, P < 0.01) relative to the wildtype strain (GMT 13.68 and 14.83) in both cohorts. None of the participants (including HCs or PLWH) could mount a NAb response against Omicron BA.5.2. In the risk model, independent risk factors for NAb seroconversion failure were the vaccination interval (hazed ration [HR] 0.316, P < 0.001) and lymphocyte counts (HR 0.409, P < 0.001). Additionally, PLWH who exhibited NAb seroconversion after vaccination had fewer initial COVID-19 symptoms when infected with Omicron.Discussion:
This study demonstrated that the third vaccination elicited better NAb responses in PLWH, when a longer interval was used between vaccinations. Since post-vaccination seroconversion reduced the number of symptoms induced by Omicron, efforts to protect PLWH with risk factors for NAb seroconversion failure may be needed during future Omicron surges. Clinical trial registration https//beta.clinicaltrials.gov/study/NCT05075070, identifier NCT05075070.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
COVID-19
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Tópicos:
Covid persistente
/
Vacunas
/
Variantes
Límite:
Humanos
Idioma:
Inglés
Revista:
Front Immunol
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
Fimmu.2023.1152695
Similares
MEDLINE
...
LILACS
LIS